![]() |
|
|
Vol. 288, Issue 2, 568-574, February 1999
Graduate School of Pharmaceutical Sciences, University of Tokyo,
Hongo, Bunkyo-ku, Tokyo, Japan (S.A., Y.K., Y.S.); and
Tsukuba Research
Institute, Banyu Pharmaceutical Co., Ltd., Okubo, Tsukuba, Japan (A.H.)
The overall disposition and hepatobiliary transport of BQ-123, an
anionic cyclopentapeptide, and three analogs were examined in rats in
vivo. Total body clearance (CLtotal) and
biliary excretion clearance (CLbile, p)
exhibited 4- to 8-fold differences between the compounds, with those
for BQ-485 and compound A having the highest and lowest values,
respectively. The CLbile, p values of
BQ-485, BQ-123, and BQ-518 were almost equal to the
CLtotal, suggesting that hepatobiliary
transport is the major elimination pathway for these compounds. Hepatic
uptake clearance (CLuptake, vivo) and
biliary excretion clearance (CLbile,
h/fT), which was defined for the
hepatic unbound concentration, were separately determined to examine
the hepatic uptake and excretion processes, respectively. Both the
CLuptake, vivo and
CLbile, h/fT of
BQ-485 were higher than those of BQ-123, whereas the corresponding
values for BQ-518 were similar to those for BQ-123. The
CLuptake, vivo and
CLbile,
h/fT of compound A were,
respectively, approximately two thirds and one half those of
BQ-123, suggesting that the lower CLbile, p value is due to the low efficiency of both the uptake and excretion processes. The CLuptake, vivo of these four
peptides in vivo was similar to the extrapolated values based on the
carrier-mediated transport activity previously assessed in vitro in
isolated rat hepatocytes. The primary active transport previously
assessed in an in vitro study in canalicular membrane vesicles was also highest for BQ-485 and lowest for compound A, similar to
CLbile, h/fT in
vivo. Thus, the transporters on both the sinusoidal and canalicular membranes determine the efficiency of the peptide overall elimination from the circulation.
This article has been cited by other articles:
![]() |
R. Nasu, Y. Kumagai, H. Kogetsu, M. Tsujimoto, H. Ohtani, and Y. Sawada PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL FOR PRALMORELIN HYDROCHLORIDE IN RATS Drug Metab. Dispos., October 1, 2005; 33(10): 1488 - 1494. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sasaki, H. Suzuki, J. Aoki, K. Ito, P. J. Meier, and Y. Sugiyama Prediction of in Vivo Biliary Clearance from the in Vitro Transcellular Transport of Organic Anions across a Double-Transfected Madin-Darby Canine Kidney II Monolayer Expressing Both Rat Organic Anion Transporting Polypeptide 4 and Multidrug Resistance Associated Protein 2 Mol. Pharmacol., September 1, 2004; 66(3): 450 - 459. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Houle, J. Raoul, J.-F. Levesque, K. S. Pang, D. A. Nicoll-Griffith, and J. M. Silva Retention of Transporter Activities in Cryopreserved, Isolated Rat Hepatocytes Drug Metab. Dispos., April 1, 2003; 31(4): 447 - 451. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Gotoh, Y. Kato, B. Stieger, P. J. Meier, and Y. Sugiyama Gender difference in the Oatp1-mediated tubular reabsorption of estradiol 17beta -D-glucuronide in rats Am J Physiol Endocrinol Metab, June 1, 2002; 282(6): E1245 - E1254. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Akhteruzzaman, Y. Kato, H. Kouzuki, H. Suzuki, A. Hisaka, B. Stieger, P. J. Meier, and Y. Sugiyama Carrier-Mediated Hepatic Uptake of Peptidic Endothelin Antagonists in Rats J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1107 - 1115. [Abstract] [Full Text] |
||||
![]() |
S. Akhteruzzaman, Y. Kato, A. Hisaka, and Y. Sugiyama Primary Active Transport of Peptidic Endothelin Antagonists by Rat Hepatic Canalicular Membrane J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 575 - 581. [Abstract] [Full Text] |
||||